Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DOXYCYCLINE vs MYOTONACHOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex. It also exhibits anti-inflammatory and anti-collagenase activities.
Myotonachol (bethanechol chloride) is a direct-acting parasympathomimetic agent that selectively stimulates muscarinic acetylcholine receptors, particularly M3 subtypes, in smooth muscle of the gastrointestinal tract and urinary bladder. It mimics the action of acetylcholine but is resistant to hydrolysis by acetylcholinesterase, leading to increased smooth muscle tone and peristalsis.
Empiric treatment of acute bacterial exacerbations of COPD,Community-acquired pneumonia,Prostatitis caused by Chlamydia trachomatis,Treatment of Lyme disease,Treatment of Rocky Mountain spotted fever,Acne vulgaris (off-label),Malaria prophylaxis (off-label)
FDA-approved: Treatment of acute postoperative and postpartum nonobstructive urinary retention and neurogenic atony of the bladder.,Off-label: Treatment of gastroesophageal reflux disease; management of chronic intestinal pseudo-obstruction; treatment of xerostomia (dry mouth) in Sjögren's syndrome or radiation-induced.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg every 12 hours or 50 mg every 6 hours.
25 mg orally three times daily. Maximum dose 100 mg four times daily.
Terminal elimination half-life is 18–24 hours in patients with normal renal function; prolonged to 20–30 hours in renal impairment; allows once or twice daily dosing.
Terminal elimination half-life: 1.5-2.5 hours (prolonged in renal impairment).
Doxycycline is partially metabolized in the liver via unspecified pathways; it is not significantly metabolized by CYP450 enzymes. Approximately 40% is excreted renally as active drug.
Bethanechol is primarily metabolized via hydrolysis by plasma esterases (pseudocholinesterases) to inactive metabolites. Minimal hepatic metabolism occurs.
Renal (40%) and fecal/biliary (60%); undergoes enterohepatic circulation; active drug and metabolites excreted in urine and feces.
Renal: 70-80% unchanged; biliary/fecal: 20-30% as metabolites.
80–93% bound to plasma proteins, primarily albumin.
~30%, bound primarily to albumin.
0.75–1.3 L/kg, indicating extensive tissue penetration; high concentrations in lung, liver, bone, and prostate.
0.3-0.6 L/kg, indicating distribution into total body water.
Oral: 90–100% (well absorbed); IV: 100%; topical: minimal systemic absorption (<10%).
Oral: 10-20% (extensive first-pass metabolism); Subcutaneous: ~80%; Intravenous: 100%.
For Cr Cl < 50 m L/min: no dosage adjustment required for most indications; for severe infections or prolonged use, consider monitoring renal function. In patients with Cr Cl < 10 m L/min, reduce dose or avoid if possible due to potential anti-anabolic effect.
GFR 30-59 m L/min: 25 mg twice daily. GFR 15-29 m L/min: 25 mg once daily. GFR <15 m L/min: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B: use with caution; no specific dose reduction recommended. Child-Pugh C: avoid use due to lack of safety data.
Child-Pugh A: no adjustment. Child-Pugh B: 25 mg twice daily. Child-Pugh C: not recommended.
For children >8 years and weighing ≤45 kg: 2.2 mg/kg every 12 hours on day 1, then 2.2 mg/kg once daily or 1.1 mg/kg every 12 hours. For children >45 kg: same as adult. For children <8 years: contraindicated due to risk of permanent tooth discoloration and enamel hypoplasia.
0.5-1 mg/kg orally three times daily; maximum 25 mg per dose.
No specific dose adjustment required; use standard adult dosing. Monitor renal function and consider potential increased risk of photosensitivity reactions. Avoid in elderly with impaired renal function if alternative agents available.
Start at 25 mg twice daily due to increased anticholinergic sensitivity.
There is no FDA black box warning for doxycycline.
None
Photosensitivity: avoid prolonged sun exposure,Esophageal injury: take with adequate fluids,Hepatotoxicity: caution in hepatic impairment,Intracranial hypertension: risk of pseudotumor cerebri,Delay in bone growth and tooth discoloration in children <8 years,C. difficile-associated diarrhea,Superinfection with resistant organisms
May cause reflex tachycardia due to hypotension; caution in patients with coronary artery disease, bradycardia, or recent myocardial infarction. Increased vagal tone may precipitate asthma attacks; avoid in asthmatics. May cause exacerbation of peptic ulcer disease. Can increase ureteral pressure; avoid in ureteral obstruction. Use cautiously in patients with epilepsy or hyperthyroidism. Monitor for cholinergic crisis (salivation, lacrimation, urination, defecation, emesis).
Hypersensitivity to tetracyclines,Children <8 years of age (except for anthrax or severe infections),Pregnancy (especially second and third trimesters)
Absolute: Hypersensitivity to bethanechol; mechanical obstruction of the gastrointestinal or urinary tract; recent gastrointestinal anastomosis or bladder surgery; hyperthyroidism; peptic ulcer disease; asthma; epilepsy; Parkinsonism; hypotension; bradycardia; coronary artery disease. Relative: Pregnancy (C); nursing mothers; patients with vagotonia or receiving quinidine or procainamide.
Dairy products (milk, cheese, yogurt), calcium-fortified foods, antacids containing aluminum, calcium, magnesium, and iron supplements can chelate doxycycline, reducing absorption. Separate intake by at least 2 hours. Alcohol is not known to interact significantly. Avoid taking with high-iron foods like spinach or red meat within 2 hours.
Food decreases absorption; take on an empty stomach. Avoid high-fat meals as they may increase side effects. No known specific food interactions.
Category D. Avoid in pregnancy. Risk of fetal harm including permanent tooth discoloration and impaired bone growth when used in second and third trimesters. First trimester use associated with neural tube defects, cardiovascular malformations, and spontaneous abortion. Hepatic necrosis in pregnant women reported.
Pregnancy Category C. First trimester: Animal studies show fetal resorption and skeletal anomalies at doses 2-3 times the maximum recommended human dose. No adequate human studies. Second trimester: Potential for premature labor due to cholinergic stimulation. Third trimester: Increased risk of uterine hyperstimulation and fetal distress if used for labor induction. Avoid use during pregnancy unless clearly needed.
Doxycycline is excreted into breast milk in low concentrations (M/P ratio ~0.2-0.6). Theoretical risk of dental staining and bone growth suppression in nursing infants. American Academy of Pediatrics considers compatible with breastfeeding due to low absorption, but alternative antibiotics preferred.
Excreted in human milk in low concentrations. M/P ratio not established. Caution advised. Potential for cholinergic adverse effects in the infant (e.g., diarrhea, increased secretions). Use only if benefit outweighs risk.
Increased renal clearance and volume of distribution during pregnancy may reduce serum concentrations, but no dose adjustment recommended due to teratogenicity. Use only if absolutely necessary with caution.
No standard dose adjustments recommended due to limited pharmacokinetic data in pregnancy. However, increased plasma volume and renal clearance may necessitate dose titration based on clinical response. Use lowest effective dose and monitor for maternal cholinergic toxicity.
Administer with a full glass of water to reduce esophageal irritation; avoid lying down for 30 minutes after dosing. Tetracyclines bind calcium, so avoid dairy, antacids, and iron within 2 hours of dosing. Use sun protection due to photosensitivity. In children under 8, pregnant, or breastfeeding, avoid due to tooth discoloration and bone growth inhibition. Monitor for superinfection, especially Clostridioides difficile. Dose adjustment not needed in renal impairment but caution in hepatic impairment.
MYOTONACHOL (bethanechol) is a cholinergic agonist used for urinary retention. Monitor for bradycardia and bronchospasm, especially in patients with asthma or cardiac disease. Administer on an empty stomach to reduce nausea. Avoid use in patients with GI obstruction or recent bladder surgery. Atropine should be readily available as an antidote.
Take exactly as prescribed; finish the full course even if you feel better.,Take with a full glass of water and remain upright for 30 minutes after.,Avoid dairy products, antacids, calcium supplements, iron, and magnesium within 2 hours of taking doxycycline.,Use sunscreen and protective clothing; avoid prolonged sun exposure as it can cause severe sunburn.,Do not take if pregnant, breastfeeding, or if you have a child under 8 years old.,Report any signs of severe diarrhea, skin rash, or difficulty swallowing to your doctor.,Store at room temperature away from moisture and heat; do not use outdated medication.
Take this medication on an empty stomach, 1 hour before or 2 hours after meals.,Avoid alcohol and caffeine, as they may worsen side effects.,Report symptoms like slow heart rate, wheezing, dizziness, or excessive sweating.,Do not drive or operate heavy machinery until you know how this drug affects you.,If you miss a dose, skip it and take the next dose at the regular time; do not double the dose.
"Hydrocortisone, a corticosteroid, may inhibit the hepatic metabolism of doxycycline, a tetracycline antibiotic, leading to increased doxycycline plasma concentrations. This elevation can potentiate doxycycline's adverse effects, such as gastrointestinal disturbance, photosensitivity, and hepatotoxicity. Clinically, this interaction may reduce the therapeutic window of doxycycline, requiring dose adjustment or alternative therapy selection."
"Ketobemidone, an opioid analgesic, may inhibit the cytochrome P450 enzyme CYP3A4, which is involved in the metabolism of doxycycline. This can lead to reduced clearance and increased plasma concentrations of doxycycline, potentially enhancing its antibiotic effects or increasing the risk of adverse effects such as photosensitivity, gastrointestinal disturbances, or hepatic toxicity."
"Clobazam, a benzodiazepine and CYP3A4 inducer, may increase the metabolism of doxycycline, a tetracycline antibiotic, reducing its plasma concentration and potentially compromising its antibacterial efficacy. This interaction could lead to subtherapeutic doxycycline levels, increasing the risk of treatment failure or microbial resistance. Conversely, doxycycline may inhibit CYP3A4, potentially elevating clobazam concentrations, though the clinical significance of this effect is less clear."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DOXYCYCLINE vs MYOTONACHOL, answered by our medical review team.
DOXYCYCLINE is a Tetracycline Antibiotic that works by Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex. It also exhibits anti-inflammatory and anti-collagenase activities.. MYOTONACHOL is a Cholinergic Agonist that works by Myotonachol (bethanechol chloride) is a direct-acting parasympathomimetic agent that selectively stimulates muscarinic acetylcholine receptors, particularly M3 subtypes, in smooth muscle of the gastrointestinal tract and urinary bladder. It mimics the action of acetylcholine but is resistant to hydrolysis by acetylcholinesterase, leading to increased smooth muscle tone and peristalsis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DOXYCYCLINE and MYOTONACHOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DOXYCYCLINE is: 100 mg orally or intravenously every 12 hours on day 1, then 100 mg every 12 hours or 50 mg every 6 hours.. The standard adult dose of MYOTONACHOL is: 25 mg orally three times daily. Maximum dose 100 mg four times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DOXYCYCLINE and MYOTONACHOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DOXYCYCLINE is classified as Category D/X. Category D. Avoid in pregnancy. Risk of fetal harm including permanent tooth discoloration and impaired bone growth when used in second and third trimesters. First trimester use as. MYOTONACHOL is classified as Category C. Pregnancy Category C. First trimester: Animal studies show fetal resorption and skeletal anomalies at doses 2-3 times the maximum recommended human dose. No adequate human studies.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.